The Virus That Was Supposed to Kill Cancer Just Killed a Company Instead
The FDA rejected Replimune's cancer-fighting virus for the second time, and the fallout was swift: 63 employees gone, manufacturing scaled back, and a company fighting to survive. The oncolytic virus pioneer's collapse reveals what happens when elegant science meets unforgiving regulatory math.
Imagine building a weapon designed to destroy cancer from the inside out. You engineer a virus, strip away the parts that make people sick, and reprogram it to hunt tumors. Then, after years of work and hundreds of millions of dollars, the FDA tells you twice that your evidence isn't good enough.
That's the story of Replimune, and it just got a lot worse.
Two Strikes and You're (Mostly) Out
On April 10, the FDA issued a Complete Response Letter for Replimune's lead drug, RP1 (vusolimogene oderparepvec). In regulatory speak, a Complete Response Letter is the agency's polite way of saying "no." This wasn't the first time, either. The FDA rejected RP1 back in July 2025, and Replimune came back swinging with new data in October.
The agency even assembled a fresh review team the second time around to avoid any bias from the first go-round. Didn't matter. The answer was still no.
Three days later, on April 13, Replimune filed a WARN notice in Massachusetts. That's the legally required heads-up companies give before mass layoffs. Sixty-three employees at its Woburn facility were let go, with cuts rolling through the end of April.
Why the FDA Wasn't Buying It
The core problem? Replimune tried to get accelerated approval (a faster pathway for serious diseases) based on a single-arm trial called IGNYTE. A single-arm trial is like taste-testing your own cooking: there's no comparison group, so it's hard to know if the results are real or just favorable circumstances.
RP1 was designed to be injected directly into melanoma tumors alongside Bristol Myers Squibb's checkpoint inhibitor Opdivo (nivolumab). The FDA's concern was straightforward: how do you know the virus is doing anything when you're also giving patients an already-approved cancer drug?
The agency's critique went deeper than that, though. The intratumoral injections themselves (literally sticking a needle into the tumor) and surgical interventions muddied the picture further. In the FDA's words, the reported response rates were potentially "artifactually increased, and may not be reproducible."
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
That's a devastating sentence for a biotech company.
A CEO Who Saw It Differently
Replimune CEO Sushil Patel didn't take it quietly. He expressed surprise at both rejections, saying the FDA hadn't raised these specific concerns during earlier review cycles. After the second rejection, Patel was blunt: "Without timely accelerated approval, the development of RP1 will not be viable."
That's not corporate spin. It's math. Replimune is a clinical-stage company, which means zero approved products and zero revenue. The company was bleeding roughly $247 million in net losses. Every quarter without a product on the market is another quarter burning through cash reserves.
For a company that once represented one of the most ambitious bets in oncolytic virus therapy, that's a brutal valuation.
What Even Is an Oncolytic Virus?
Think of it like a Trojan horse for cancer. Scientists take a virus (in Replimune's case, herpes simplex) and genetically modify it so it can only replicate inside tumor cells. When the virus kills those cells, it spills their contents into the surrounding tissue, essentially waving a flag that says "hey, immune system, cancer is over here." The goal is to turn a "cold" tumor (one the immune system ignores) into a "hot" one that the body actively fights.
It's an elegant idea. And it's not just Replimune chasing it. The oncolytic virus market is projected to grow significantly in the coming years, with numerous companies developing drugs in this space spanning adenoviruses, vaccinia viruses, and herpes-based platforms.
Amgen's T-VEC (Imlygic), approved for melanoma back in 2015, remains the best-known example. In combination trials with checkpoint inhibitors, it achieved a 35.7% overall response rate compared to 16% for the checkpoint inhibitor alone. Companies like Genelux, Candel Therapeutics, and CG Oncology are pushing their own candidates into Phase III trials for ovarian cancer, prostate cancer, and beyond.
The field isn't dead. But Replimune's stumble is a cautionary tale about what happens when the clinical evidence doesn't match the scientific promise.
The Bigger Picture: Small Biotechs Under Siege
Replimune isn't suffering alone. The first quarter of 2026 saw 33 biotech layoff announcements, and while that's roughly half the 63 reported in Q1 2025, the individual stories are still brutal.
Theravance Biopharma halved its headcount after a Phase 3 failure. Gossamer Bio cut 48% of its workforce (77 people) when its pulmonary hypertension drug flopped; the stock cratered 78%. IO Biotech filed for bankruptcy after the FDA rejected its cancer vaccine. f5 Therapeutics simply shut down after six years, with its CEO calling the environment "brutal" for early-stage biotechs.
The pattern is grimly consistent: a clinical or regulatory setback hits, the stock tanks, cash gets tight, and the layoffs follow like dominoes. For companies without approved products generating revenue, there's no safety net.
What's Left for Replimune?
Not nothing, actually. The company still has a randomized Phase 3 trial running for RP1, the kind of head-to-head comparison study the FDA wanted all along. That trial is enrolling patients with advanced melanoma and comparing RP1 plus Opdivo against physician's choice.
There's also a long-term safety study tracking patients who received RP1, RP2, or RP3 (Replimune's earlier pipeline candidates) in previous trials. But details on RP2 and RP3 development timelines are scarce, and the company hasn't announced any partnerships to share the financial burden.
So the question becomes whether Replimune can survive long enough for that Phase 3 data to read out. With 63 fewer employees, scaled-back U.S. manufacturing, and quarterly losses running around $0.70 to $0.80 per share, the runway is getting shorter by the quarter.
The science behind oncolytic viruses is still compelling. Teaching a virus to eat cancer cells and then recruit the immune system? That's the kind of idea that gets researchers out of bed in the morning. But good science needs good data, and good data needs money, and money needs investors who still believe.
For Replimune, belief just got a lot more expensive.
Science & Discovery4 min read
Flagship Just Invented a New Type of Drug (No, Seriously)
Flagship Pioneering, the firm that built Moderna, just unveiled Serif Biomedicines and a brand-new drug category called Modified DNA. It promises the durability of gene therapy and the flexibility of mRNA, without rewriting your genome. The catch? It still has to prove it works in humans.
